Kezar Life Sciences, Inc. financial data

Symbol
KZR on Nasdaq
Industry
Pharmaceutical Preparations
Location
4000 Shoreline Court, Suite 300, South San Francisco, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 25, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 870 % -43.2%
Debt-to-equity 20.5 % +40.4%
Return On Equity -58.7 % -27.9%
Return On Assets -48.7 % -21.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 7.31M shares -90%
Common Stock, Shares, Outstanding 7.3M shares +0.35%
Entity Public Float 43M USD -75.1%
Common Stock, Value, Issued 7K USD 0%
Weighted Average Number of Shares Outstanding, Basic 7.29M shares +0.48%
Weighted Average Number of Shares Outstanding, Diluted 7.29M shares +0.48%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
Research and Development Expense 65.7M USD -23.3%
General and Administrative Expense 23.4M USD -11.9%
Operating Income (Loss) -90.6M USD +18.7%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -83.7M USD +17.8%
Earnings Per Share, Basic -11.5 USD/shares +18.2%
Earnings Per Share, Diluted -11.5 USD/shares +18.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 41.7M USD +17.6%
Marketable Securities, Current 90.5M USD -45.4%
Accounts Receivable, after Allowance for Credit Loss, Current 7M USD
Other Assets, Current 935K USD +14.3%
Assets, Current 137M USD -33.6%
Property, Plant and Equipment, Net 2.89M USD -26%
Operating Lease, Right-of-Use Asset 1.89M USD -60.5%
Other Assets, Noncurrent 2.42M USD -56.8%
Assets 145M USD -34.6%
Accounts Payable, Current 3.65M USD -55.8%
Employee-related Liabilities, Current 2.72M USD -26.8%
Accrued Liabilities, Current 7.94M USD +22.4%
Liabilities, Current 20.3M USD +14.6%
Operating Lease, Liability, Noncurrent 2.33M USD -60.3%
Liabilities 27.8M USD -17.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax -162K USD -24.6%
Retained Earnings (Accumulated Deficit) -434M USD -23.9%
Stockholders' Equity Attributable to Parent 117M USD -37.7%
Liabilities and Equity 145M USD -34.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -22.9M USD -9.6%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 20.4M USD +24.5%
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 7.3M shares +0.35%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.46M USD +43.1%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 41.7M USD +17.6%
Interest Paid, Excluding Capitalized Interest, Operating Activities 336K USD +8.39%
Deferred Tax Assets, Valuation Allowance 102M USD +24.2%
Deferred Tax Assets, Gross 103M USD +23.1%
Operating Lease, Liability 5.85M USD -34%
Depreciation 1M USD -9.09%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -83.8M USD +17.1%
Lessee, Operating Lease, Liability, to be Paid 6.44M USD -37.6%
Property, Plant and Equipment, Gross 9.34M USD +0.06%
Operating Lease, Liability, Current 3.53M USD +17.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.42M USD -39.9%
Lessee, Operating Lease, Liability, to be Paid, Year One 4.03M USD +3.47%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 591K USD -59.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 347K USD -91.5%
Deferred Tax Assets, Operating Loss Carryforwards 50.3M USD +17.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 5.01M USD +22.9%
Lessee, Operating Lease, Liability, to be Paid, Year Four 347K USD +23.1%
Operating Lease, Payments 3.01M USD +17.4%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 260K USD +0.39%
Deferred Tax Assets, Net of Valuation Allowance 659K USD -48.4%
Share-based Payment Arrangement, Expense 13M USD -28.3%
Interest Expense 1.6M USD +6.87%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%